Limits...
AXIN2 rs2240308 polymorphism contributes to increased cancer risk: evidence based on a meta-analysis.

Wu Z, Sun Y, Tang S, Liu C, Zhu S, Wei L, Xu H - Cancer Cell Int. (2015)

Bottom Line: Asian populations showed similar results.GA + AA: OR = 1.45, 95 % CI = 1.18-1.79.All I (2)  < 50 % and P Q  > 0.100 for heterogeneity).

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Laboratory, Guigang City People's Hospital, 1 Zhongshan Middle Road, Guigang, 537100, Guangxi People's Republic of China.

ABSTRACT

Background: Variants in the axis inhibition 2 (AXIN2) gene might alter the protein's structure or function or create a multiprotein destruction complex in the Wnt signaling pathway and thus affect an individual's susceptibility to cancer. The objective of this study is to evaluate broadly the evidence available for the AXIN2 rs2240308 polymorphism and risk of cancer.

Methods: A comprehensive literature search was undertaken for eligible studies in Embase, PubMed, and Cochrane Library up to Nov 30, 2014. Odds ratios (ORs) and the corresponding 95 % confidence intervals (CIs) were used to measure the strength of the models.

Results: Eight articles (10 case-control studies with 1,502 cases and 1,590 controls) were included in this analysis. Overall, the AXIN2 rs2240308 polymorphism was associated with a significant increase in the risk of cancer (G allele vs. A allele: OR = 1.21, 95 % CI = 1.05-1.40, I (2)  = 39.5 % and P Q  = 0.094 for heterogeneity; GG vs. AA: OR = 1.30, 95 % CI = 1.04-1.63, I (2)  = 35.9 % and P Q  = 0.121 for heterogeneity; GG vs. GA + AA: OR = 1.36, 95 % CI = 1.17-1.58, I (2)  = 19.5 % and P Q  = 0.263 for heterogeneity). Asian populations showed similar results. Stratified analysis by cancer types indicated that the AXIN2 rs2240308 polymorphism increases the risk of lung cancer (G allele vs. A allele: OR = 1.36, 95 % CI = 1.17-1.59; GA vs. AA: OR = 1.43, 95 % CI = 1.01-2.02; GG vs. AA: OR = 1.93, 95 % CI = 1.36-2.75; GG + GA vs. AA: OR = 1.65, 95 % CI = 1.18-2.30; GG vs. GA + AA: OR = 1.45, 95 % CI = 1.18-1.79. All I (2)  < 50 % and P Q  > 0.100 for heterogeneity).

Conclusions: This study showed that the AXIN2 rs2240308 polymorphism contribute to increasing the risk of cancer, especially lung cancer in Asian populations.

No MeSH data available.


Related in: MedlinePlus

Flow diagram of included studies for this meta-analysis
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4496878&req=5

Fig1: Flow diagram of included studies for this meta-analysis

Mentions: Figure 1 shows the flow of studies. Based on the search terms, eight articles that included ten case-control studies with 1,502 cases and 1,590 controls were identified as suitable for a meta-analysis [10–16, 23]. Kanzaki H et al.’s article [16] was separated into three studies because the researchers studied three cancers. Four articles were on Caucasians, four on Asians; three studies were on lung cancer and two on prostate cancer. The other cancers included colorectal cancer, head and neck cancer, astrocytoma, ovarian cancer, and papillary thyroid carcinoma. HEW was calculated with the genotypes of control population, and one article did not fall into HWE. The quality scores showed the eight studies were “high quality.” Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used in 6 studies. The source of the control population was divided into hospital-based (HB) and population-based (PB). The characteristics of the eligible and included studies are listed in Table 2.Fig. 1


AXIN2 rs2240308 polymorphism contributes to increased cancer risk: evidence based on a meta-analysis.

Wu Z, Sun Y, Tang S, Liu C, Zhu S, Wei L, Xu H - Cancer Cell Int. (2015)

Flow diagram of included studies for this meta-analysis
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4496878&req=5

Fig1: Flow diagram of included studies for this meta-analysis
Mentions: Figure 1 shows the flow of studies. Based on the search terms, eight articles that included ten case-control studies with 1,502 cases and 1,590 controls were identified as suitable for a meta-analysis [10–16, 23]. Kanzaki H et al.’s article [16] was separated into three studies because the researchers studied three cancers. Four articles were on Caucasians, four on Asians; three studies were on lung cancer and two on prostate cancer. The other cancers included colorectal cancer, head and neck cancer, astrocytoma, ovarian cancer, and papillary thyroid carcinoma. HEW was calculated with the genotypes of control population, and one article did not fall into HWE. The quality scores showed the eight studies were “high quality.” Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used in 6 studies. The source of the control population was divided into hospital-based (HB) and population-based (PB). The characteristics of the eligible and included studies are listed in Table 2.Fig. 1

Bottom Line: Asian populations showed similar results.GA + AA: OR = 1.45, 95 % CI = 1.18-1.79.All I (2)  < 50 % and P Q  > 0.100 for heterogeneity).

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Laboratory, Guigang City People's Hospital, 1 Zhongshan Middle Road, Guigang, 537100, Guangxi People's Republic of China.

ABSTRACT

Background: Variants in the axis inhibition 2 (AXIN2) gene might alter the protein's structure or function or create a multiprotein destruction complex in the Wnt signaling pathway and thus affect an individual's susceptibility to cancer. The objective of this study is to evaluate broadly the evidence available for the AXIN2 rs2240308 polymorphism and risk of cancer.

Methods: A comprehensive literature search was undertaken for eligible studies in Embase, PubMed, and Cochrane Library up to Nov 30, 2014. Odds ratios (ORs) and the corresponding 95 % confidence intervals (CIs) were used to measure the strength of the models.

Results: Eight articles (10 case-control studies with 1,502 cases and 1,590 controls) were included in this analysis. Overall, the AXIN2 rs2240308 polymorphism was associated with a significant increase in the risk of cancer (G allele vs. A allele: OR = 1.21, 95 % CI = 1.05-1.40, I (2)  = 39.5 % and P Q  = 0.094 for heterogeneity; GG vs. AA: OR = 1.30, 95 % CI = 1.04-1.63, I (2)  = 35.9 % and P Q  = 0.121 for heterogeneity; GG vs. GA + AA: OR = 1.36, 95 % CI = 1.17-1.58, I (2)  = 19.5 % and P Q  = 0.263 for heterogeneity). Asian populations showed similar results. Stratified analysis by cancer types indicated that the AXIN2 rs2240308 polymorphism increases the risk of lung cancer (G allele vs. A allele: OR = 1.36, 95 % CI = 1.17-1.59; GA vs. AA: OR = 1.43, 95 % CI = 1.01-2.02; GG vs. AA: OR = 1.93, 95 % CI = 1.36-2.75; GG + GA vs. AA: OR = 1.65, 95 % CI = 1.18-2.30; GG vs. GA + AA: OR = 1.45, 95 % CI = 1.18-1.79. All I (2)  < 50 % and P Q  > 0.100 for heterogeneity).

Conclusions: This study showed that the AXIN2 rs2240308 polymorphism contribute to increasing the risk of cancer, especially lung cancer in Asian populations.

No MeSH data available.


Related in: MedlinePlus